Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.

Pappagallo, Marco; Kosten, Thomas R; Gorodetzky, Charles W; Vocci, Frank J; Sapienza, Frank L; De Martin, Sara; Comai, Stefano; Mattarei, Andrea; Inturrisi, Charles E; Manfredi, Paolo L.

Afiliação

Pappagallo M; Relmada Therapeutics, Inc., Coral Gables, FL, USA.
Kosten TR; Baylor College of Medicine, MD Anderson Cancer Center, University of Houston, Houston, TX, USA.
Gorodetzky CW; Consultant in Pharmaceutical Medicine, Kansas City, MO, USA.
Vocci FJ; Friends Research Institute, Baltimore, MD, USA.
Sapienza FL; The Drug and Chemical Advisory Group LLC, Fairfax, VA, USA.
De Martin S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Comai S; Department of Pharmaceutical and Pharmacological Sciences, and Department of Biomedical Sciences, University of Padua, Padua, Italy.
Mattarei A; Department of Psychiatry, McGill University, Montreal, QC, Canada.
Inturrisi CE; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Manfredi PL; Relmada Therapeutics, Inc., Coral Gables, FL, USA.

Mol Psychiatry ; 2024 May 28.

Article em En | MEDLINE | ID: mdl-38806691

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article